Evidence map›Paper›PMID 41167668›Full record

ArticleIn vivo (Athens, Greece)

Hepatoprotective Potential of

Li-Wei Chen, I-Wen Wu, Tzu-Chien Cheng, Lun-Ching Chang, Cheng-Kai Hsu, Ling Yeung, Liang-Che Chang, Shih-Chi Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Li-Wei ChenDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
I-Wen WuDivision of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
Tzu-Chien ChengDepartment of Pathology, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
Lun-Ching ChangDepartment of Mathematics and Statistics, Florida Atlantic University, Boca Raton, FL, U.S.A.
Cheng-Kai HsuDepartment of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
Ling YeungDepartment of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
Liang-Che ChangDepartment of Pathology, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
Shih-Chi SuWhole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.; ssu1@cgmh.org.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a significant global health burden, with increasing evidence pointing to gut microbiota as a modifiable contributor to disease pathogenesis. Yet, the causality of gut microbiota in liver health is not fully established. This study aimed to clarify a causal relationship of specific gut microbes with MASLD. MATERIALS AND

methodsIn this pre-clinical study, we assessed the hepatoprotective potential of

resultsOur

conclusion

Indexed as

BacteroidesFatty LiverNon-alcoholic Fatty Liver DiseaseAnimalsDiet, High-FatDisease Models, AnimalDysbiosisGastrointestinal MicrobiomeHumansLipid PeroxidationLiverMaleMiceProbioticsBacteroides eggerthiiGut microbiotainflammationmetabolic dysfunction-associated steatotic liver diseaseoxidative stress

Identifiers

PMID41167668
PMCPMC12588227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.